375 related articles for article (PubMed ID: 26210956)
1. Small-molecule kinase inhibitors: an analysis of FDA-approved drugs.
Wu P; Nielsen TE; Clausen MH
Drug Discov Today; 2016 Jan; 21(1):5-10. PubMed ID: 26210956
[TBL] [Abstract][Full Text] [Related]
2. Properties of FDA-approved small molecule protein kinase inhibitors: A 2020 update.
Roskoski R
Pharmacol Res; 2020 Feb; 152():104609. PubMed ID: 31862477
[TBL] [Abstract][Full Text] [Related]
3. Properties of FDA-approved small molecule protein kinase inhibitors: A 2021 update.
Roskoski R
Pharmacol Res; 2021 Mar; 165():105463. PubMed ID: 33513356
[TBL] [Abstract][Full Text] [Related]
4. Properties of FDA-approved small molecule protein kinase inhibitors.
Roskoski R
Pharmacol Res; 2019 Jun; 144():19-50. PubMed ID: 30877063
[TBL] [Abstract][Full Text] [Related]
5. Cutaneous toxicity of FDA-approved small-molecule kinase inhibitors.
Du J; Yan H; Xu Z; Yang B; He Q; Wang X; Luo P
Expert Opin Drug Metab Toxicol; 2021 Nov; 17(11):1311-1325. PubMed ID: 34743659
[TBL] [Abstract][Full Text] [Related]
6. Assessing the translational value of pre-clinical studies for clinical response rate in oncology: an exploratory investigation of 42 FDA-approved small-molecule targeted anticancer drugs.
Liu WA; Yu L; Morcos PN; Mercier F; Brennan BJ
Cancer Chemother Pharmacol; 2020 Jun; 85(6):1015-1027. PubMed ID: 32424570
[TBL] [Abstract][Full Text] [Related]
7. Early accelerated approval for highly targeted cancer drugs.
Chabner BA
N Engl J Med; 2011 Mar; 364(12):1087-9. PubMed ID: 21428763
[No Abstract] [Full Text] [Related]
8. Kinase Inhibitors FDA Approved 2018-2023: Drug Targets, Metabolic Pathways, and Drug-Induced Toxicities.
Latham BD; Geffert RM; Jackson KD
Drug Metab Dispos; 2024 May; 52(6):479-492. PubMed ID: 38286637
[TBL] [Abstract][Full Text] [Related]
9. FDA-approved small-molecule kinase inhibitors.
Wu P; Nielsen TE; Clausen MH
Trends Pharmacol Sci; 2015 Jul; 36(7):422-39. PubMed ID: 25975227
[TBL] [Abstract][Full Text] [Related]
10. Hepatotoxicity of FDA-approved small molecule kinase inhibitors.
Jiang H; Jin Y; Yan H; Xu Z; Yang B; He Q; Luo P
Expert Opin Drug Saf; 2021 Mar; 20(3):335-348. PubMed ID: 33356646
[No Abstract] [Full Text] [Related]
11. A cross-sectional study of the FDA approved indications and supporting pivotal trials of small-molecular kinase inhibitors in cancer therapies with the biomarker of cancer driver gene.
Huang Y; Xiong W; Ma L; Wu H
Int J Cancer; 2022 Dec; 151(12):2107-2114. PubMed ID: 35860988
[TBL] [Abstract][Full Text] [Related]
12. Kinase-targeting small-molecule inhibitors and emerging bifunctional molecules.
Goebel GL; Qiu X; Wu P
Trends Pharmacol Sci; 2022 Oct; 43(10):866-881. PubMed ID: 35589447
[TBL] [Abstract][Full Text] [Related]
13. Trends in kinase drug discovery: targets, indications and inhibitor design.
Attwood MM; Fabbro D; Sokolov AV; Knapp S; Schiöth HB
Nat Rev Drug Discov; 2021 Nov; 20(11):839-861. PubMed ID: 34354255
[TBL] [Abstract][Full Text] [Related]
14. Properties of FDA-approved small molecule protein kinase inhibitors: A 2022 update.
Roskoski R
Pharmacol Res; 2022 Jan; 175():106037. PubMed ID: 34921994
[TBL] [Abstract][Full Text] [Related]
15. Small molecules in targeted cancer therapy: advances, challenges, and future perspectives.
Zhong L; Li Y; Xiong L; Wang W; Wu M; Yuan T; Yang W; Tian C; Miao Z; Wang T; Yang S
Signal Transduct Target Ther; 2021 May; 6(1):201. PubMed ID: 34054126
[TBL] [Abstract][Full Text] [Related]
16. TransMolecular receives FDA approval for 131-I-TM-601 IND application.
Expert Rev Anticancer Ther; 2002 Apr; 2(2):139. PubMed ID: 12113233
[No Abstract] [Full Text] [Related]
17. FDA's proposed regulations to expand access to investigational drugs for treatment use: the status quo in the guise of reform.
Rossen BR
Food Drug Law J; 2009; 64(1):183-223. PubMed ID: 19998746
[TBL] [Abstract][Full Text] [Related]
18. Accelerated drug approval: FDA may get tougher; companies cite hurdles.
Goozner M
J Natl Cancer Inst; 2011 Mar; 103(6):455-7. PubMed ID: 21393609
[No Abstract] [Full Text] [Related]
19. Targeting non-receptor tyrosine kinases using small molecule inhibitors: an overview of recent advances.
Hojjat-Farsangi M
J Drug Target; 2016; 24(3):192-211. PubMed ID: 26211367
[TBL] [Abstract][Full Text] [Related]
20. Expanded Access to Investigational Drugs: What Physicians and the Public Need to Know about FDA and Corporate Processes.
Finkelstein PE
AMA J Ethics; 2015 Dec; 17(12):1142-6. PubMed ID: 26698587
[No Abstract] [Full Text] [Related]
[Next] [New Search]
